Kybella

DRUG6 trials

Sponsors

Massachusetts General Hospital, AbbVie, Glonova Pharma Co., Ltd, The Maas Clinic

Conditions

Cutaneous NeurofibromaDeformity; SkinFacial ContouringFat RedistributionLipodystrophyLipomaNeurofibromas, CutaneousNeurofibromatosis 1

Phase 1

Tolerability of Device Based Therapies for Neurofibromatosis Type 1 Cutaneous Neurofibromas

CompletedNCT04730583

Massachusetts General HospitalCutaneous Neurofibroma

Start: 2021-06-02End: 2024-04-19Updated: 2025-02-21

Dosing and Tolerability of Deoxycholic Acid vs. Polidocanol in the Treatment of Neurofibromatosis Type 1 Cutaneous Neurofibromas

CompletedNCT06120036

Massachusetts General HospitalNeurofibromatosis 1

Start: 2022-12-06End: 2025-01-09Updated: 2025-02-21

Assessing the Efficacy of Repeat, Monthly Treatments of Deoxycholate for NF1 Associated Cutaneous Neurofibromas (cNFs)

Enrolling by invitationNCT06300502

Massachusetts General HospitalNeurofibromas, Cutaneous, Neurofibromatosis 1

Start: 2025-04-08End: 2027-02-01Target: 15Updated: 2026-04-22

Intralesional Ronkyla Plus Injection for the Treatment of Superficial Lipoma

RecruitingNCT07237425

Glonova Pharma Co., LtdLipoma, Submental Fullness

Start: 2025-11-14End: 2028-08-31Target: 56Updated: 2026-10-02

Phase 4

A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVÉDERM® Products, KYBELLA, CoolSculpting Elite and SkinMedica Products

CompletedNCT06783621

AbbVieFacial Contouring

Start: 2025-01-16End: 2026-03-20Updated: 2026-05-22

Safety and Efficacy of Deoxycholate Treatment of Small Fatty Deformities ( SFD)

CompletedNCT07880301

The Maas ClinicDeformity; Skin, Fat Redistribution, Lipodystrophy

Start: 2018-02-20End: 2021-12-25Updated: 2026-10-19